Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

ImmuCell Corp. engages in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company is headquartered in Portland, Maine and currently employs 25 full-time employees. The firm operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. The firm has developed products that provide immediate immunity to newborn dairy and beef cattle, and is developing product line extensions of its existing products that address mastitis. The firm`s lead product, First Defense, is manufactured from cows` colostrum utilizing its vaccine and milk protein purification technologies. Its Wipe Out Dairy Wipes are made from a non-woven fabric that allows for a vigorous cleaning. The company also developed California Mastitis Test (CMT), which is used for bulk tank, as well as individual cow sample monitoring and is used to determine which quarter of the udder is mastitic. Its product development initiative is Mast Out, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows.
Website: immucell.com



Growth: Good revenue growth rate >200%, there is acceleration compared to average historical growth rates 30.7%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -9.6%. On average the margin is improving steadily. Gross margin is normal, +26.3%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 67% of quarters (showing a gain of +$0.03 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 6.1% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 78.8% higher than minimum and 17.0% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued >100x by EV / Sales multiple , the company can be >100% undervalued

Insiders: For the last 3 months insiders bought company shares on $0.1 mln (0.169% of cap.)

Key Financials (Download financials)

Ticker: ICCC
Share price, USD:  (0.0%)6.31
year average price 5.92  


year start price 5.05 2025-02-12

max close price 7.60 2025-06-20

min close price 4.56 2025-11-18

current price 6.31 2026-02-11
Common stocks: 7 742 860

Dividend Yield:  0.0%
EV / Sales: 0.0x
Margin (EBITDA LTM / Revenue): -9.6%
Fundamental value created in LTM:
Market Cap ($m): 49
Net Debt ($m): 12
EV (Enterprise Value): 61
Price to Book: 1.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-12-24globenewswire.com

ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain®

2025-12-04zacks.com

ImmuCell's Two-Product Edge in Cattle Health Fuels Growth

2025-11-20zacks.com

ICCC Stock Down Despite Y/Y Q3 Earnings Improvement & Margin Strength

2025-11-14seekingalpha.com

ImmuCell Corporation (ICCC) Q3 2025 Earnings Call Transcript

2025-08-21zacks.com

ImmuCell Swings to Q2 Profit on Strong Sales, Shares Still Slide

2025-08-15seekingalpha.com

ImmuCell Corporation (ICCC) Q2 2025 Earnings Call Transcript

2025-06-05globenewswire.com

ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders

2025-05-19zacks.com

ImmuCell Reports Y/Y Q1 Earnings Growth on Record Sales & Margin Gains

2025-05-12globenewswire.com

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2025

2025-02-20globenewswire.com

ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2024
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol ICCC ICCC ICCC ICCC ICCC ICCC ICCC ICCC ICCC ICCC ICCC ICCC ICCC ICCC
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 811 641 811 641 811 641 811 641 811 641 811 641 811 641 811 641 811 641 811 641 811 641 811 641 811 641 811 641
fillingDate 2025-11-13 2025-08-14 2024-11-13 2024-08-13 2024-05-14 2023-11-13 2023-08-10 2023-05-11 2022-11-21
acceptedDate 2025-11-13 16:08:17 2025-08-14 16:06:33 2025-03-28 16:05:24 2024-11-13 16:05:28 2024-08-13 16:05:51 2024-05-14 16:06:15 2024-04-01 16:05:50 2023-11-13 16:05:51 2023-08-10 16:06:15 2023-05-11 16:05:58 2023-03-29 16:05:54 2022-11-21 16:06:12 2022-03-30 16:06:09 2021-03-30 07:56:25
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 6M 6M 26M 6 012M 5M 7M 17M 5M 4M 3M 19M 5M 19M 15M
costOfRevenue 3M 4M 19M 4 428M 4M 5M 13M 4M 2M 3M 11M 3M 11M 8M
grossProfit 2M 3M 8M 1 584M 1M 2M 4M 1M 1M 300 775 8M 2M 9M 7M
grossProfitRatio 0.429 0.437 0.263 0.225 0.316 0.235 0.295 0.087 0.385
researchAndDevelopmentExpenses 694 311 831 858 4M 786M 1M 1M 4M 1M 1M 1M 4M 1M 4M 4M
generalAndAdministrativeExpenses 0 720 418 2M 528 267 601 634 531 938 2M 514 952 529 056 567 019 2M 466 342 2M 2M
sellingAndMarketingExpenses 0 696 086 3M 844M 984 957 800 923 3M 817 486 719 789 879 427 3M 1M 3M 2M
sellingGeneralAndAdministrativeExpenses 2M 1M 6M 844M 2M 1M 5M 817 486 1M 1M 5M 1M 4M 4M
otherExpenses 0 0 0 528M 0 532M 527 000 514 952 529M 107 0 0 0 0
operatingExpenses 2M 2M 10M 2 158M 3M 3M 10M 2M 2M 3M 10M 2M 8M 8M
costAndExpenses 5M 6M 28M 6 586M 7M 8M 23M 7M 5M 6M 21M 5M 19M 17M
interestIncome 41 468 48 113 77 702 7880 13 264 9527 0 23 696 14 806 40 631 153 100 55 009 18 810 27 440
interestExpense 134 516 124 795 568 725 133 336 142 386 146 003 0 135 929 86 658 89 984 348 536 89 430 314 359 412 687
depreciationAndAmortization 679 090 668 231 3M 675 122 670 958 667 253 3M 700 411 684 795 697 648 2M 0 2M 2M
ebitda 543 798 1M 1M -575M -716 945 367 200 -3M -1M -606 813 -2M 349 990 -617 000 3M 2M
ebitdaratio 0.099 0.201 -0.096 -0.131 0.051 -0.219 -0.172 -0.452 -0.129
operatingIncome 20 075 569 562 -2M -575M -1M -300 050 -6M -1M -1M -2M -2M -617 000 257 385 -1M
operatingIncomeRatio 0.004 0.088 -0.096 -0.253 -0.041 -0.219 -0.369 -0.655 -0.129
totalOtherIncomeExpensesNet -155 367 -65 778 -506 414 -125M -143 679 -136 478 -21 893 244 275 77 -57 489 -186 805 -34 000 -326 512 347 883
incomeBeforeTax -135 292 503 784 -2M -700M -2M -436 528 -6M -939 771 -1M -2M -2M -651 000 -69 127 -1M
incomeBeforeTaxRatio -0.025 0.078 -0.117 -0.28 -0.06 -0.174 -0.39 -0.671 -0.136
incomeTaxExpense 4456 1904 10 056 1M 1340 1340 4627 229 1525 1525 8000 4000 9165 -10000
netIncome -139 748 501 880 -2M -702M -2M -437 868 -6M -940 000 -1M -2M -2M -655 000 -78 292 -1M
netIncomeRatio -0.025 0.078 -0.117 -0.28 -0.06 -0.174 -0.391 -0.672 -0.137
eps -0.02 0.056 -0.26 -85.94 -0.2 -0.057 -0.75 -0.12 -0.18 -0.3 -0.32 -0.085 -0.01 -0.14
epsdiluted -0.02 0.056 -85.94 -0.2 -0.057 -0.12 -0.18 -0.3 -0.085
weightedAverageShsOut 9M 9M 8M 8M 8M 8M 8M 8M 8M 8M 8M 8M 8M 7M
weightedAverageShsOutDil 9M 9M 8M 8M 8M 8M 8M 8M 8M 8M 8M 8M 8M 7M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-28 2024-04-01 2023-03-29 2022-03-30 2021-03-30
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -491 023 0 -195 436 -295 549 -385 247
ebit -2M -5M -2M 237 391 -714 345
nonOperatingIncomeExcludingInterest -19 645 -527 000 -161 350 19 994 -666 008
netIncomeFromContinuingOperations -2M -6M -2M -78 292 -1M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -2M -6M -2M -78 292 -1M
epsDiluted -0.26 -0.75 -0.32 -0.01 -0.14

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol ICCC ICCC ICCC ICCC ICCC ICCC ICCC ICCC ICCC ICCC ICCC ICCC ICCC ICCC
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 811 641 811 641 811 641 811 641 811 641 811 641 811 641 811 641 811 641 811 641 811 641 811 641 811 641 811 641
fillingDate 2025-11-13 2025-08-14 2024-11-13 2024-08-13 2024-05-14 2023-11-13 2023-08-10 2023-05-11 2022-11-21
acceptedDate 2025-11-13 16:08:17 2025-08-14 16:06:33 2025-03-28 16:05:24 2024-11-13 16:05:28 2024-08-13 16:05:51 2024-05-14 16:06:15 2024-04-01 16:05:50 2023-11-13 16:05:51 2023-08-10 16:06:15 2023-05-11 16:05:58 2023-03-29 16:05:54 2022-11-21 16:06:12 2022-03-30 16:06:09 2021-03-30 07:56:25
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 4M 6M 4M 4M 1M 960 347 978 741 2M 1M 3M 6M 9M 10M 8M
shortTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 -468 0
cashAndShortTermInvestments 4M 6M 4M 4M 1M 960 347 978 741 2M 1M 3M 6M 9M 10M 8M
netReceivables 3M 2M 4M 2M 2M 3M 2M 2M 2M 2M 2M 2M 3M 2M
inventory 10M 8M 7M 7M 7M 7M 8M 7M 8M 6M 6M 5M 3M 2M
otherCurrentAssets 527 868 419 653 0 277 146 196 181 426 096 39 733 722M 456M 734M 0 552 431 0 800
totalCurrentAssets 17M 17M 15M 14M 11M 11M 11M 12M 11M 12M 14M 16M 16M 12M
propertyPlantEquipmentNet 29M 29M 30M 30 413M 31M 32M 32M 32M 33M 31M 31M 30M 28M 28M
goodwill 95 557 95 557 95 557 95 557 95 557 95 557 95 557 95 557 95 557 95 557 95 557 95 557 95 557 95 557
intangibleAssets 4776 9552 19 104 23 880 28 656 33 432 38 208 42 984 47 760 52 536 57 312 62 088 76 416 95 520
goodwillAndIntangibleAssets 100 333 105 109 114 661 119 437 124 213 128 989 133 765 138 541 143 317 148 093 152 869 157 645 171 973 191 077
longTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 44 344 53 619 33 368 148M 37 679 182 725 57 655 70 041 82 459 87 781 76 628 24 567 26 115 26 173
totalNonCurrentAssets 29M 30M 30M 30 561M 31M 32M 32M 33M 33M 31M 31M 30M 28M 28M
otherAssets 0 0 0 -30 531M 0 0 0 -22 0 0 351 439 312 406
totalAssets 46M 47M 45M 44M 42M 43M 44M 45M 44M 43M 45M 46M 44M 40M
accountPayables 972 144 1M 943 637 883 214 438 147 737 333 887 733 779 846 918 399 794 853 789 997 759 335 745 044 602 347
shortTermDebt 2M 2M 1M 2M 2M 2M 1M 1M 2M 2M 1M 1M 812 207 760 337
taxPayables 0 0 0 1166 0 4391 3051 964 735 0 4890 3728 2141 0
deferredRevenue 0 0 0 0 0 4390 0 -1 848M -2 049M 0 0 0 0 0
otherCurrentLiabilities 1M 1M 0 2M 2M 1M 306 780 1 849M 2 051M 944 882 0 934 582 0 0
totalCurrentLiabilities 4M 4M 4M 4M 5M 4M 4M 3M 4M 4M 3M 3M 3M 2M
longTermDebt 12M 12M 9M 14M 14M 10M 11M 15M 13M 11M 9M 12M 8M 9M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 0 0 0 0 0 4M 0 0 0 0 0 10M 0 0
totalNonCurrentLiabilities 12M 12M 13M 14M 14M 14M 15M 15M 13M 11M 11M 12M 9M 10M
otherLiabilities 0 0 0 0 0 1 0 467 0 0 400 -39 252 606
capitalLeaseObligations 4M 4M 5M 5M 5M 4M 5M 4M 4M 2M 2M 2M 1M 1M
totalLiabilities 16M 17M 18M 18M 18M 18M 19M 19M 17M 15M 14M 14M 12M 12M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 910 563 910 563 904 240 889 641 789 639 781 417 781 417 781 417 781 417 781 417 781 417 781 417 781 417 729 901
retainedEarnings -12M -12M -14M -15M -14M -12M -12M -11M -10M -9M -6M -5M -4M -4M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 0 -0 -0 -0 -0 0 0 -0 0 -0 0
othertotalStockholdersEquity 41M 41M 40M 37M 36M 36M 36M 36M 36M
totalStockholdersEquity 30M 30M 28M 26M 23M 25M 25M 26M 27M 28M 30M 32M 33M 28M
totalEquity 30M 30M 28M 26M 23M 25M 25M 26M 27M 28M 30M 32M 33M 28M
totalLiabilitiesAndStockholdersEquity 46M 47M 44M 42M 43M 45M 44M 43M 46M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 46M 47M 45M 44M 42M 43M 44M 45M 44M 43M 45M 46M 44M 40M
totalInvestments 0 0 0 -3 805M 0 0 0 0 0 0 0 0 -468 0
totalDebt 14M 14M 15M 16M 16M 16M 17M 17M 15M 13M 12M 13M 10M 11M
netDebt 10M 8M 11M 12M 15M 15M 16M 15M 14M 10M 7M 4M 89 030 3M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-28 2024-04-01 2023-03-29 2022-03-30 2021-03-30
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 4M 2M 2M 3M 2M
otherReceivables 40 555 0 42 178 26 484 67 621
prepaids 360 207 454 152 363 877 268 713 252 840
totalPayables 949 452 890 784 794 887 747 185 602 347
otherPayables 5815 3051 4890 2141 0
accruedExpenses 2M 943 000 1M 867 065 747 880
capitalLeaseObligationsCurrent 432 072 644 276 31 764 108 012 100 512
capitalLeaseObligationsNonCurrent 4M 4M 2M 1M 1M
treasuryStock -138 482 -138 482 -147 233 -158 171 -175 392
additionalPaidInCapital 41M 36M 36M 36M 31M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q2 2025 q1 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol ICCC ICCC ICCC ICCC ICCC ICCC ICCC ICCC ICCC ICCC ICCC ICCC ICCC ICCC ICCC
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 811 641 811 641 811 641 811 641 811 641 811 641 811 641 811 641 811 641 811 641 811 641 811 641 811 641 811 641 811 641
fillingDate 2025-08-14 2025-05-14 2024-11-13 2024-08-13 2024-05-14 2023-11-13 2023-08-10 2023-05-11 2022-11-21 2022-08-11
acceptedDate 2025-08-14 16:06:33 2025-05-14 16:06:03 2025-03-28 16:05:24 2024-11-13 16:05:28 2024-08-13 16:05:51 2024-05-14 16:06:15 2024-04-01 16:05:50 2023-11-13 16:05:51 2023-08-10 16:06:15 2023-05-11 16:05:58 2023-03-29 16:05:54 2022-11-21 16:06:12 2022-08-11 16:07:09 2022-03-30 16:06:09 2021-03-30 07:56:25
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
netIncome 501 880 1M -2M -701 690 -2M -437 868 -6M -940 000 -1M -2M -2M -877 457 -684 148 -78 292 -1M
depreciationAndAmortization 668 231 675 967 3M 675 122 670 958 667 253 3M 700 411 684 795 656 910 2M 632 321 629 384 2M 2M
deferredIncomeTax 0 0 0 0 0 0 0 -68 -76 0 0 0 0 30 963 -14 631
stockBasedCompensation 66 714 52 215 326 000 77 557 98 021 81 110 368 866 96 434 75 657 96 116 266 244 85 122 61 634 144 313 253 135
changeInWorkingCapital 399 770 -579 000 -406 516 -663 690 1M 135 198 -2M -440 198 -84 313 -1M -2M -1M 364 746 -2M 532 261
accountsReceivables 967 602 424 708 -2M -357 463 672 082 -437 149 0 -365 737 591 451 -331 699 935 629 -288 126 1M -897 428 -159 636
inventory -937 060 -244 743 699 218 -160 846 -150 043 662 278 0 150 318 -1M -289 788 -3M -714 674 -1M -997 460 425 742
accountsPayables 225 519 -531 203 362 606 0 430 259 19 980 156 995 -86 311 249 324 -259M 341.614 19 549 -199 654 246M 300M
otherWorkingCapital 143 709 -227 764 117 410 -145 381 404 201 -109 911 -2M -138 468 282 566 258M 179 901 -118 697 0 -245M -300M
otherNonCashItems -35 097 -22 327 -91 762 -26 630 -12 072 1M 260 818 75 667 22 225 18 757 28 800 3920 1842 18 557 -780 353
netCashProvidedByOperatingActivities 2M 2M 357 903 -639 331 581 780 418 505 -5M -507 754 -681 426 -3M -2M -1M 373 458 954 170 1M
investmentsInPropertyPlantAndEquipment -155 159 -329 050 -465 725 -88 412 -110 741 -70 356 -2M -420 515 -708 488 -682 166 -4M -734 309 -943 290 -3M -4M
acquisitionsNet 29 232 0 0 0 0 0 0 2383 76 0 11 000 0 0 15 290 45 600
purchasesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 -15 290 -2M
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 996 000 3M
otherInvestingActivites 0 0 0 4500 0 -115 127 0 15 0 0
netCashUsedForInvestingActivites -125 927 -329 050 -88 412 -106 241 -70 356 -533 259 -708 412 -682 151 -734 309 -943 290
debtRepayment -381 438 -380 106 -368 250 -364 350 -361 506 -2M -251 901 -251 376 -223 102 -228 431
commonStockIssued 329 892 19 434 4M 252 749 0 0 0 0 0 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0 0
otherFinancingActivites -24 902 -42 975 0 252 749 -5037 4M 0 1 000 000 0 24 352
netCashUsedProvidedByFinancingActivities -76 448 -403 647 3M -111 601 -366 543 2M -251 901 748 624 -223 102 -204 079
effectOfForexChangesOnCash 0 0 0 0 0 0 0 -2M 0 0 0 0 0 0 0
netChangeInCash 1M 841 139 3M 2M 363 938 -18 394 -5M 535 151 -2M -3M -4M -2M -773 911 3M 656 644
cashAtEndOfPeriod 6M 5M 4M 4M 1M 960 347 978 741 2M 1M 3M 6M 9M 11M 10M 7M
cashAtBeginningOfPeriod 5M 4M 978 741 1M 960 347 978 741 6M 1M 3M 6M 10M 11M 12M 7M 6M
operatingCashFlow 2M 2M 357 903 -639 331 581 780 418 505 -5M -507 754 -681 426 -3M -2M -1M 373 458 954 170 1M
capitalExpenditure -155 159 -329 050 -465 725 -88 412 -110 741 -70 356 -2M -420 515 -708 488 -682 166 -4M -734 309 -943 290 -3M -4M
freeCashFlow 1M 1M -107 822 -727 743 471 039 348 149 -7M -928 269 -1M -3M -6M -2M -569 832 -2M -3M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link
filingDate 2025-03-28 2024-04-01 2023-03-29 2022-03-30 2021-03-30
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 4500 2474 11 000 15 290 45 600
netCashProvidedByInvestingActivities -461 225 -2M -4M -2M -3M
netDebtIssuance -1M 2M 1M -368 271 2M
longTermNetDebtIssuance -1M 2M 1M -368 271 2M
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 4M 0 0 4M 0
netCommonStockIssuance 4M 18 760 0 4M 0
commonStockIssuance 4M 0 31M 4M 9
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -5037 -62 772 11 364 13 965 -53 127
netCashProvidedByFinancingActivities 3M 2M 1M 4M 2M
incomeTaxesPaid 7293 0 4923 5110 4581
interestPaid 528 907 0 338 516 308 682 481 408

Earning call transcript

2025 q3
2025-11-14 ET (fiscal 2025 q3)
2025 q2
2025-08-15 ET (fiscal 2025 q2)
2025 q1
2025-05-15 ET (fiscal 2025 q1)
2024 q4
2025-02-26 ET (fiscal 2024 q4)
2024 q3
2024-11-14 ET (fiscal 2024 q3)
2024 q2
2024-08-14 ET (fiscal 2024 q2)
2024 q1
2024-05-15 ET (fiscal 2024 q1)
2023 q4
2024-02-28 ET (fiscal 2023 q4)
2023 q3
2023-11-14 ET (fiscal 2023 q3)
2023 q2
2023-08-11 ET (fiscal 2023 q2)
2023 q1
2023-05-12 ET (fiscal 2023 q1)
2022 q4
2023-02-22 ET (fiscal 2022 q4)
2022 q3
2022-11-22 ET (fiscal 2022 q3)
2022 q2
2022-08-12 ET (fiscal 2022 q2)
2022 q1
2022-05-13 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 8
2026-01-08 21:13 ET
ImmuCell Corporation published news for 2025 q4
SEC form 8
2026-01-08 21:13 ET
ImmuCell Corporation published news for 2025 q4
SEC form 8
2025-12-29 13:00 ET
ImmuCell Corporation published news for 2025 q3
SEC form 8
2025-12-29 13:00 ET
ImmuCell Corporation published news for 2025 q3
SEC form 10
2025-11-13 21:08 ET
ImmuCell Corporation reported for 2025 q3
SEC form 8
2025-11-13 21:07 ET
ImmuCell Corporation published news for 2025 q3
SEC form 8
2025-11-13 21:07 ET
ImmuCell Corporation reported for 2025 q3
SEC form 8
2025-10-07 20:06 ET
ImmuCell Corporation published news for 2025 q3
SEC form 8
2025-10-07 20:06 ET
ImmuCell Corporation reported for 2025 q3
SEC form 10
2025-08-14 20:06 ET
ImmuCell Corporation reported for 2025 q2
SEC form 8
2025-08-14 20:05 ET
ImmuCell Corporation published news for 2025 q2
SEC form 8
2025-08-14 20:05 ET
ImmuCell Corporation reported for 2025 q2
SEC form 8
2025-07-09 00:00 ET
ImmuCell Corporation published news for 2025 q2
SEC form 8
2025-07-09 00:00 ET
ImmuCell Corporation reported for 2025 q2
SEC form 8
2025-06-25 19:48 ET
ImmuCell Corporation published news for 2025 q1
SEC form 8
2025-06-25 19:48 ET
ImmuCell Corporation published news for 2025 q1
SEC form 10
2025-05-14 20:06 ET
ImmuCell Corporation reported for 2025 q1
SEC form 8
2025-05-14 20:05 ET
ImmuCell Corporation published news for 2025 q1
SEC form 8
2025-05-14 20:05 ET
ImmuCell Corporation reported for 2025 q1
SEC form 10
2025-05-14 00:00 ET
ImmuCell Corporation reported for 2025 q1
SEC form 8
2025-04-08 00:00 ET
ImmuCell Corporation published news for 2025 q1
SEC form 8
2025-04-08 00:00 ET
ImmuCell Corporation reported for 2025 q1
SEC form 10
2025-03-28 20:05 ET
ImmuCell Corporation reported for 2024 q4
SEC form 10
2025-03-28 00:00 ET
ImmuCell Corporation reported for 2024 q4
SEC form 8
2025-02-25 00:00 ET
ImmuCell Corporation published news for 2024 q4
SEC form 8
2025-02-25 00:00 ET
ImmuCell Corporation reported for 2024 q4
SEC form 8
2025-01-10 00:00 ET
ImmuCell Corporation published news for 2024 q4
SEC form 8
2025-01-10 00:00 ET
ImmuCell Corporation reported for 2024 q4
SEC form 10
2024-11-13 16:05 ET
ImmuCell Corporation reported for 2024 q3
SEC form 8
2024-11-13 16:05 ET
ImmuCell Corporation published news for 2024 q3
SEC form 8
2024-11-13 16:05 ET
ImmuCell Corporation reported for 2024 q3
SEC form 10
2024-11-13 00:00 ET
ImmuCell Corporation reported for 2024 q3
SEC form 8
2024-10-08 00:00 ET
ImmuCell Corporation published news for 2024 q3
SEC form 8
2024-10-08 00:00 ET
ImmuCell Corporation reported for 2024 q3
SEC form 10
2024-08-13 16:05 ET
ImmuCell Corporation reported for 2024 q2
SEC form 8
2024-08-13 16:05 ET
ImmuCell Corporation published news for 2024 q2
SEC form 8
2024-08-13 16:05 ET
ImmuCell Corporation reported for 2024 q2
SEC form 10
2024-08-13 00:00 ET
ImmuCell Corporation reported for 2024 q2
SEC form 8
2024-07-09 00:00 ET
ImmuCell Corporation published news for 2024 q2
SEC form 8
2024-07-09 00:00 ET
ImmuCell Corporation reported for 2024 q2
SEC form 10
2024-05-14 16:06 ET
ImmuCell Corporation reported for 2024 q1
SEC form 8
2024-05-14 16:05 ET
ImmuCell Corporation published news for 2024 q1
SEC form 8
2024-05-14 16:05 ET
ImmuCell Corporation reported for 2024 q1
SEC form 10
2024-05-14 00:00 ET
ImmuCell Corporation reported for 2024 q1
SEC form 8
2024-04-09 00:00 ET
ImmuCell Corporation published news for 2024 q1
SEC form 8
2024-04-09 00:00 ET
ImmuCell Corporation published news for 2024 q1
SEC form 10
2024-04-01 16:05 ET
ImmuCell Corporation published news for 2023 q4
SEC form 10
2024-04-01 00:00 ET
ImmuCell Corporation published news for 2023 q4
SEC form 8
2024-02-27 16:05 ET
ImmuCell Corporation published news for 2023 q4
SEC form 8
2024-02-27 16:05 ET
ImmuCell Corporation reported for 2023 q4
SEC form 8
2024-01-08 00:00 ET
ImmuCell Corporation published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
ImmuCell Corporation published news for 2023 q4
SEC form 10
2023-11-13 16:05 ET
ImmuCell Corporation reported for 2023 q3
SEC form 8
2023-11-13 16:05 ET
ImmuCell Corporation reported for 2023 q3
SEC form 10
2023-11-13 00:00 ET
ImmuCell Corporation reported for 2023 q3
SEC form 8
2023-10-05 00:00 ET
ImmuCell Corporation published news for 2023 q3
SEC form 10
2023-08-10 16:06 ET
ImmuCell Corporation reported for 2023 q2
SEC form 6
2023-08-10 16:05 ET
ImmuCell Corporation reported for 2023 q2
SEC form 10
2023-08-10 00:00 ET
ImmuCell Corporation reported for 2023 q2
SEC form 8
2023-08-10 00:00 ET
ImmuCell Corporation reported for 2023 q2
SEC form 6
2023-07-21 09:04 ET
ImmuCell Corporation published news for 2023 q2
SEC form 6
2023-07-11 16:05 ET
ImmuCell Corporation published news for 2023 q2
SEC form 8
2023-07-11 00:00 ET
ImmuCell Corporation published news for 2023 q2
SEC form 6
2023-06-29 13:02 ET
ImmuCell Corporation published news for 2023 q1
SEC form 6
2023-06-21 16:05 ET
ImmuCell Corporation published news for 2023 q1
SEC form 6
2023-05-11 16:06 ET
ImmuCell Corporation reported for 2023 q1
SEC form 10
2023-05-11 16:05 ET
ImmuCell Corporation reported for 2023 q1
SEC form 10
2023-05-11 00:00 ET
ImmuCell Corporation reported for 2023 q1
SEC form 8
2023-05-11 00:00 ET
ImmuCell Corporation reported for 2023 q1
SEC form 6
2023-04-28 10:13 ET
ImmuCell Corporation published news for 2023 q1
SEC form 6
2023-04-18 17:10 ET
ImmuCell Corporation published news for 2023 q1
SEC form 6
2023-04-05 16:05 ET
ImmuCell Corporation published news for 2023 q1
SEC form 8
2023-04-05 00:00 ET
ImmuCell Corporation published news for 2023 q1
SEC form 10
2023-03-29 16:05 ET
ImmuCell Corporation reported for 2022 q4
SEC form 10
2023-03-29 00:00 ET
ImmuCell Corporation reported for 2022 q4
SEC form 6
2023-02-28 09:24 ET
ImmuCell Corporation published news for 2022 q4
SEC form 6
2023-02-21 16:06 ET
ImmuCell Corporation reported for 2022 q4
SEC form 8
2023-02-21 00:00 ET
ImmuCell Corporation reported for 2022 q4
SEC form 6
2023-02-01 17:25 ET
ImmuCell Corporation published news for 2022 q4
SEC form 6
2023-01-09 16:10 ET
ImmuCell Corporation published news for 2022 q4
SEC form 8
2023-01-09 00:00 ET
ImmuCell Corporation published news for 2022 q4
SEC form 6
2022-11-21 16:58 ET
ImmuCell Corporation published news for 2022 q3
SEC form 10
2022-11-21 16:06 ET
ImmuCell Corporation reported for 2022 q3
SEC form 6
2022-11-21 09:49 ET
ImmuCell Corporation published news for 2022 q3
SEC form 6
2022-11-21 09:44 ET
ImmuCell Corporation published news for 2022 q3
SEC form 10
2022-11-21 00:00 ET
ImmuCell Corporation reported for 2022 q3
SEC form 8
2022-11-21 00:00 ET
ImmuCell Corporation reported for 2022 q3
SEC form 6
2022-11-10 16:24 ET
ImmuCell Corporation published news for 2022 q3
SEC form 6
2022-11-10 16:22 ET
ImmuCell Corporation published news for 2022 q3
SEC form 8
2022-11-10 00:00 ET
ImmuCell Corporation published news for 2022 q3
SEC form 6
2022-10-05 06:35 ET
ImmuCell Corporation published news for 2022 q3
SEC form 8
2022-10-05 00:00 ET
ImmuCell Corporation published news for 2022 q3
SEC form 6
2022-08-17 16:37 ET
ImmuCell Corporation published news for 2022 q2
SEC form 10
2022-08-11 16:07 ET
ImmuCell Corporation reported for 2022 q2
SEC form 6
2022-08-11 16:05 ET
ImmuCell Corporation published news for 2022 q2
SEC form 10
2022-08-11 00:00 ET
ImmuCell Corporation reported for 2022 q2
SEC form 8
2022-08-11 00:00 ET
ImmuCell Corporation reported for 2022 q2
SEC form 6
2022-07-27 20:05 ET
ImmuCell Corporation published news for 2022 q2
SEC form 8
2022-07-07 00:00 ET
ImmuCell Corporation published news for 2022 q2
SEC form 6
2022-07-06 18:15 ET
ImmuCell Corporation published news for 2022 q2
SEC form 6
2022-06-21 06:14 ET
ImmuCell Corporation published news for 2022 q1
SEC form 6
2022-06-16 10:14 ET
ImmuCell Corporation published news for 2022 q1
SEC form 10
2022-05-12 16:06 ET
ImmuCell Corporation reported for 2022 q1
SEC form 6
2022-05-12 16:05 ET
ImmuCell Corporation published news for 2022 q1
SEC form 10
2022-05-12 00:00 ET
ImmuCell Corporation reported for 2022 q1
SEC form 8
2022-05-12 00:00 ET
ImmuCell Corporation reported for 2022 q1
SEC form 6
2022-04-28 08:12 ET
ImmuCell Corporation published news for 2022 q1
SEC form 6
2022-04-12 08:46 ET
ImmuCell Corporation published news for 2022 q1
SEC form 6
2022-04-11 15:08 ET
ImmuCell Corporation published news for 2022 q1
SEC form 8
2022-04-11 00:00 ET
ImmuCell Corporation published news for 2022 q1
SEC form 10
2022-03-30 16:06 ET
ImmuCell Corporation published news for 2021 q4
SEC form 10
2022-03-30 00:00 ET
ImmuCell Corporation published news for 2021 q4
SEC form 6
2022-03-24 14:19 ET
ImmuCell Corporation published news for 2021 q4
SEC form 6
2022-02-22 16:06 ET
ImmuCell Corporation published news for 2021 q4
SEC form 8
2022-02-22 00:00 ET
ImmuCell Corporation published news for 2021 q4
SEC form 6
2022-02-11 14:23 ET
ImmuCell Corporation published news for 2021 q4
SEC form 6
2022-01-05 10:39 ET
ImmuCell Corporation published news for 2021 q4
SEC form 8
2022-01-05 00:00 ET
ImmuCell Corporation published news for 2021 q4
SEC form 6
2021-11-15 16:05 ET
ImmuCell Corporation published news for 2021 q3
SEC form 10
2021-11-15 16:05 ET
ImmuCell Corporation published news for 2021 q3
SEC form 10
2021-11-15 00:00 ET
ImmuCell Corporation published news for 2021 q3
SEC form 8
2021-11-15 00:00 ET
ImmuCell Corporation published news for 2021 q3
SEC form 6
2021-10-06 09:41 ET
ImmuCell Corporation published news for 2021 q3
SEC form 8
2021-10-06 00:00 ET
ImmuCell Corporation published news for 2021 q3
SEC form 6
2021-08-24 15:55 ET
ImmuCell Corporation published news for 2021 q2
SEC form 10
2021-08-12 16:07 ET
ImmuCell Corporation published news for 2021 q2
SEC form 6
2021-08-12 16:05 ET
ImmuCell Corporation published news for 2021 q2
SEC form 10
2021-08-12 00:00 ET
ImmuCell Corporation published news for 2021 q2
SEC form 6
2021-07-07 14:19 ET
ImmuCell Corporation published news for 2021 q2
SEC form 6
2021-07-06 07:00 ET
ImmuCell Corporation published news for 2021 q2
SEC form 6
2021-06-17 14:50 ET
ImmuCell Corporation published news for 2021 q1
SEC form 10
2021-05-13 16:07 ET
ImmuCell Corporation published news for 2021 q1
SEC form 6
2021-05-13 16:05 ET
ImmuCell Corporation published news for 2021 q1
SEC form 10
2021-05-13 00:00 ET
ImmuCell Corporation published news for 2021 q1
SEC form 6
2021-04-29 08:42 ET
ImmuCell Corporation published news for 2021 q1
SEC form 6
2021-04-15 13:49 ET
ImmuCell Corporation published news for 2021 q1
SEC form 6
2021-04-07 10:37 ET
ImmuCell Corporation published news for 2021 q1
SEC form 10
2021-03-30 07:56 ET
ImmuCell Corporation published news for 2020 q4
SEC form 6
2021-02-23 14:30 ET
ImmuCell Corporation published news for 2020 q4
SEC form 6
2021-01-07 10:21 ET
ImmuCell Corporation published news for 2020 q4
SEC form 6
2020-12-16 17:34 ET
ImmuCell Corporation published news for 2020 q3
SEC form 6
2020-11-12 16:25 ET
ImmuCell Corporation published news for 2020 q3
SEC form 10
2020-11-12 16:08 ET
ImmuCell Corporation published news for 2020 q3
SEC form 6
2020-10-06 11:57 ET
ImmuCell Corporation published news for 2020 q3